¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal change nephropathy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • minimal identifiable odor
    ÃÖ¼ÒÀνij¿»õ, ÃÖ¼ÒºÐÇØÃë°¢
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal visible angle
    Ãּҽð¢
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮, ÃÖ¼ÒÀÏÀϿ䱸·®
  • minimal identifiable odor
    ÃÖ¼ÒºÐÇØÃë°¢, ÃÖ¼ÒÀνij¿»õ
  • minimal nerve excitability test
    ÃּҽŰæÀڱذ˻ç
  • minimal stimulating test
    ¹Ì¾àÁÖÀÔÀڱؽÃÇè
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • frequency change
    Á֯ļö º¯È­
  • genotypic change
    À¯ÀüÀÚÇüº¯ÀÌ.
  • hyaline change
    À¯¸®Áú º¯È­
  • hypertensive change
    °íÇ÷¾Ð¼º º¯È­ ¾ÈÀú(äÑî¼)ÀÇ .
  • irreversible change
    ºñ°¡¿ª¼º(ުʦæ½àõ) º¯È­(ܨûù).
  • isothermal change
    µî¿Âº¯È­(¡­Ü¨ûù).
  • life change scale
    »ýȰº¯È­Ã´µµ(~ô©Óø)
  • malignant change
    ¾Ç¼ºº¯È­(¡­Ü¨ûù).
  • mood, change
  • phasic change
    À§»ó¼º º¯È­(êÈßÓàõܨûù).
  • physical change
    ¹°¸®º¯È­(ÚªìµÜ¨ûù).
  • rachitic change
    ±¸·ç¼º º¯È­( ×§àõܨûù).
  • rachitic change
    ±¸·ç¼º º¯È­(±¸×§àõܨûù)
  • retinal change of hypertension
    °íÇ÷¾ÐÀÇ ¸Á¸·º¯È­.
  • retinal change of hypertension
    °íÇ÷¾ÐÀÇ ¸Á¸·º¯È­(ÍÔúìäâ¡­¡­Ü¨ûù)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MCGN mesangiocapillary glomerulonephritis; minimal change glomerulonephritis; mixed cryoglobulinemia with...
MCINS minimal change idiopathic nephrotic syndrome
MCL maximum containment laboratory; medial collateral ligament; midclavicular line; midcostal line; mini...
MCNS minimal change nephrotic syndrome
MGC megacolon; minimal glomerular change
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CAN Chronic allograft nephropathy
DN Diabetic Nephropathy
EN Endemic nephropathy
HIV AN HIV associated nephropathy
Hivan Human immunodeficiency virus associated nephropathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lifestyle change
    »ýȰ ¾ç½ÄÀÇ º¯È­
  • macular change
    ¹ÝÁ¡¼º º¯È­
  • mucosal change
    Á¡¸· º¯È­
  • oral mucosa change
    ±¸°­ Á¡¸· º¯È­
  • organic dystrophic change
    ±âÁúÀû ÀÌ¿µ¾ç¼º À§Ãà º¯È­
  • osteolytic change
    °ñ ¿ëÇØ º¯È­
  • painless change
    ¹«Åë º¯È­
  • papular change
    ±¸Áø¼º º¯È­
  • parakeratotic lip change
    ºÎÀü °¢È­¼º ÀÔ¼ú º¯È­
  • pustular change
    ³óÆ÷¼º º¯È­
  • rachitic change
    ±¸·ç¼º º¯È­
  • regressive change
    ÅðÇ༺ º¯È­
  • sclerodermal change
    °øÇǼº º¯È­
  • senile change
    ³ëÀμº º¯È­
    ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó »ýü¿¡¼­ ¼­¼­È÷ ÀϾ´Â º¯È­.
  • shaggy hyperplastic change
    ²¬²ô·¯¿î °úÁõ½Ä º¯È­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
minimal anaesthetic concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal brain dysfunction An inability to control behaviour due to difficulty in processing neural stimuli.
(12 Dec 1998)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á